Supplier News Breaks Archives
Breckenridge brings Cymbalta generic to market
June 13th, 2014
BOCA RATON, Fla. – Breckenridge Pharmaceutical Inc. has launched duloxetine delayed-release capsules, a medication for depression.
Breckenridge said Thursday that its product, which received final approval from the Food and Drug Administration, is being manufactured and supplied by its parent company, Laboratorios Dr. Esteve S.A. in Barcelona, Spain, and will be available in strengths of 20 mg, 30 mg and 60 mg.
Duloxetine delayed-release capsules are AB-rated to Eli Lilly & Co.'s Cymbalta, which is indicated for the treatment of major depressive disorder.
According to Breckenridge, this milestone signifies the first vertically integrated product developed and commercialized between Breckenridge and Esteve.